Glecaprevir and pibrentasvir combination therapy for hepatitis C virus-infected Japanese patients on hemodialysis

Table 2 The demographics of patients with previous DAA treatment failure and other baseline clinical characteristics

Case	Duration span (weeks)	Genotype	Liver cirrhosis	Previous DAA treatment	L31	Y93	D168	SVR 12	Discontinuation therapy	Adverse events
1	8	2a						+
2	12	1b	+	DCV+ASV	L31 V>M>L	Y93 H	D168 E	+		Pruritus
3	8	2a						+		Pruritus
4	8	1b			Wild	Wild	Wild	+
5	8	2b						+
6	8	1b			Wild	Wild	Wild	+		Pruritus
7	12	2a	+					+		Pruritus, fatigue
8	8	2a						+
9	8	2b						+
10	12	1b	+	DCV+ASV	L31 M	Y93 H	D168 D>E	+
11	8	1b			Wild	Wild	Wild	+
12	12	1b	+		Wild	Wild	Wild	+	Weeks 8 (pruritus)	Bloating, pruritus
13	12	1b		DCV+ASV	L31 M	Y93 H	D168E	+	Weeks 6 (cellulitis)	Cellulitis
14	8	1b			Wild	Wild	Wild	+
15	8	2a						+		Pruritus
16	8	2b						Relapse
17	8	2a						+		Headache
18	8	1b			Wild	Wild	Wild	+		Pruritus

ISSN: 2059-1381